CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.


Dr. Hill on the Role of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

September 11th 2020

Brian T. Hill, MD, PhD, discusses the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

Dr. Costa on Remaining Challenges With CAR T-Cell Therapy in Multiple Myeloma

September 9th 2020

Luciano J. Costa, MD, PhD, discusses remaining challenges with investigational CAR T-cell therapies in relapsed/refractory multiple myeloma.

FDA Approval Sought for Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

September 4th 2020

A supplemental biologics license application has been filed with the FDA for axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma following 2 or more previous lines of systemic therapy.

Dr. Shah on Early Benefit of Orvacabtagene Autoleucel in Relapsed/Refractory Myeloma

September 3rd 2020

Nina Shah, MD, discusses the phase 1/2 EVOLVE study with orvacabtagene autoleucel in relapsed/refractory multiple myeloma.

CAR T-Cell Therapies Continue to Raise the Bar in Lymphoma Management

August 27th 2020

Pashna N. Munshi, MD, discusses the CAR T-cell therapies that have emerged in the lymphoma space and highlights the next steps for research with these products.

Questions Remain as CAR T-Cell Therapy Prepares to Transform Relapsed/Refractory Myeloma Treatment

August 24th 2020

Luciano J. Costa, MD, discusses the emerging role of CAR T-cell therapy in relapsed/refractory multiple myeloma, investigational products such as ide-cel, orva-cel, and JNJ-4528, and early intervention strategies to manage the toxicities associated with these products.

FDA Halts Phase 1 Trial With P-PSMA-101 in mCRPC Following Patient Death

August 18th 2020

The FDA has placed a clinical hold on the phase 1 P-PSMA-101-001 trial examining the autologous CAR T-cell therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer.

ALLO-501– and ALLO-647–Based Lymphodepletion Well Tolerated in Advanced Non-Hodgkin Lymphoma

August 17th 2020

Sattva Neelapu, MD, discussed findings from the first-in-human phase 1 ALPHA study which demonstrated encouraging short-term efficacy, along with manageable toxicities, with ALLO-501 and ALLO-647.

Investigational Immunotherapies Elicit Unprecedented Responses in Relapsed/Refractory Myeloma

August 17th 2020

Nina Shah MD, discusses the future of CAR T-cell therapy and bispecific antibodies in multiple myeloma.

Dr. Shah on BCMA-Directed CAR T-Cell Therapy Research in R/R Multiple Myeloma

August 14th 2020

Nina Shah, MD, discusses ​ongoing research with BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma.

Dr. Shah on Updated Efficacy of JNJ-4528 in Relapsed/Refractory Myeloma

August 12th 2020

Nina Shah, MD, discusses the updated efficacy findings of JNJ-4528 from the phase 1b/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.

Dr. Shah on the Future of CAR T-Cell Therapy in Multiple Myeloma

August 12th 2020

Nina Shah, MD, discusses the future of CAR T-cell therapy in multiple myeloma. 

Dr. Park on ​the Benefits of Off-the-Shelf CAR T-Cell Therapy in ALL

August 10th 2020

Jae Park, MD, discusses ​the benefits of off-the-shelf CAR T-cell therapy in acute lymphoblastic leukemia.

Dr. Park on Considerations of CAR T-Cell Therapy in Relapsed/Refractory ALL

August 7th 2020

Jae Park, MD, discusses considerations for CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia.

Dr. Abid on Challenges With CAR T-Cell Therapy During the COVID-19 Pandemic

August 6th 2020

Muhammad Bilal Abid, MD, MRCP, discusses challenges with CAR-T cell therapy during the coronavirus disease 2019 pandemic.

CD30-Targeted CAR T-Cell Therapy Elicits Durable Responses in Relapsed/Refractory Hodgkin Lymphoma

August 6th 2020

A CD30-targeted CAR T-cell therapy was found to elicit a high rate of durable complete responses (CRs) in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.

Dr. Shaughnessy on Addressing Challenges With CAR T-Cell Therapy in Hematologic Malignancies

August 5th 2020

Paul J. Shaughnessy, MD, discusses the challenges faced with CAR T-cell therapy in hematologic malignancies.

Shaughnessy Speaks to the Rapidly Evolving Role of CAR T-cell Therapy in Hematologic Malignancies

August 5th 2020

Paul J. Shaughnessy, MD, discusses how CAR T-cell therapy is being utilized in hematologic malignancies, challenges faced with this modality, and ongoing research efforts being made to better leverage its use.

Tisagenlecleucel Shows Clinically Meaningful Benefit in Relapsed/Refractory Follicular Lymphoma

August 4th 2020

Tisagenlecleucel was found to elicit clinically meaningful activity in patients with relapsed/refractory follicular lymphoma, meeting the phase 2 ELARA trial’s primary end point of complete response rate.

Dr. Shaughnessy on Challenges With CAR T-Cell Therapy in Hematologic Malignancies

August 4th 2020

Paul J. Shaughnessy, MD, discusses challenges with CAR T-cell therapy in relapsed/refractory hematologic malignancies.